Ann Clin Microbiol.  2022 Sep;25(3):73-78. 10.5145/ACM.2022.25.3.1.

EUCAST v.12.0 review focused on changes

• Song SA

• KMID: 2533952
• DOI: http://doi.org/10.5145/ACM.2022.25.3.1

Abstract

Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoint tables are commonly used as guidelines for the interpretation of antimicrobial susceptibility testing results. These are updated annually to reflect new and revised antimicrobial susceptibility breakpoints. EUCAST v.12.0, which was published in January 2022, presents updated meropenem-vaborbactam breakpoints for Enterobacterales and Pseudomonas aeruginosa. It also suggests new breakpoints of susceptibility to various antibiotics for Vibrio spp. Flow charts were updated for Streptococcus pneumoniae and Haemophilus influenzae, and the breakpoints for anaerobic bacteria were divided according to each species. Furthermore, recommendations were made for cases without antimicrobial susceptibility testing breakpoints and links to several rationale and guidance documents were provided for technical convenience.

Keyword

Antimicrobial susceptibility testing; Breakpoint; EUCAST v.12.0

Figure

• 

  Fig. 1. Box-plots of cycle threshold (Ct) values distributions according to the concordance results between Exdia Ag and Real-Q assays. Solid lines in box-plots represent the Ct value medians, box-plots and whiskers represent the Ct values distribution. Abbreviations: TP, Exdia Ag-positive/Real-Q-positive samples; FN, Exdia Ag-negative/Real-Qpositive samples; RdRp, RNA-dependent RNA polymerase gene; E, envelope gene; Exdia Ag, Exdia COVID-19 antigen; Real-Q, Real-Q 2019-nCoV Detection KIT.

Reference

1. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020;25. .

2. Hong KH, Kim GJ, Roh KH, Sung H, Lee J, Kim SY, et al. Update of guidelines for laboratory diagnosis of COVID-19 in Korea. Ann Lab Med 2022;42:391-7. .

3. Diel R and Nienhaus A. Point-of-care COVID-19 antigen testing in German emergency rooms - a cost-benefit analysis. Pulmonology 2021;28:164-72. .

4. Caruana G, Croxatto A, Kampouri E, Kritikos A, Opota O, Foerster M, et al. Implementing SARS-CoV-2 rapid antigen testing in the emergency ward of a Swiss university hospital: the INCREASE study. Microorganisms 2021;9:798. .

5. Leli C, Di Matteo L, Gotta F, Cornaglia E, Vay D, Megna I, et al. Performance of a SARSCoV-2 antigen rapid immunoassay in patients admitted to the emergency department. Int J Infect Dis 2021;110:135-40. .

6. Möckel M, Corman VM, Stegemann MS, Hofmann J, Stein A, Jones TC, et al. SARSCoV-2 antigen rapid immunoassay for diagnosis of COVID-19 in the emergency department. Biomarkers 2021;26:213-20. .

7. Greub G, Caruana G, Schweitzer M, Imperiali M, Muigg V, Risch M, et al. Multicenter technical validation of 30 rapid antigen tests for the detection of SARS-CoV-2 (VALIDATE). Microorganisms 2021;9:2589. .

8. Kritikos A, Caruana G, Brouillet R, Miroz JP, Abed-Maillard S, Stieger G, et al. Sensitivity of rapid antigen testing and RT-PCR performed on nasopharyngeal swabs versus saliva samples in COVID-19 hospitalized patients: results of a prospective comparative trial (RESTART). Microorganisms 2021;9:1910. .

9. Routsias JG, Mavrouli M, Tsoplou P, Dioikitopoulou K, Tsakris A. Diagnostic performance of rapid antigen tests (RATs) for SARS-CoV-2 and their efficacy in monitoring the infectiousness of COVID-19 patients. Sci Rep 2021;11:22863. .

10. Corman VM, Haage VC, Bleicker T, Schmidt ML, Mühlemann B, Zuchowski M, et al. Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests: a singlecentre laboratory evaluation study. Lancet Microbe 2021;2:e311-9. .

11. Brümmer LE, Katzenschlager S, Gaeddert M, Erdmann C, Schmitz S, Bota M, et al. Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: a living systematic review and metaanalysis. PLoS Med 2021;18:e1003735. .

12. Kweon OJ, Lim YK, Kim HR, Choi Y, Kim MC, Choi SH, et al. Evaluation of rapid SARS-CoV-2 antigen tests, AFIAS COVID-19 Ag and ichroma COVID-19 Ag, with serial nasopharyngeal specimens from COVID-19 patients. PLoS One 2021;16:e0249972. .

13. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020;581:465-9. .

14. Kim MC, Cui C, Shin KR, Bae JY, Kweon OJ, Lee MK, et al. Duration of culturable SARSCoV-2 in hospitalized patients with Covid-19. N Engl J Med 2021;384:671-3. .

15. van Kampen JJA, van de Vijver DAMC, Fraaij PLA, Haagmans BL, Lamers MM, Okba N, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). Nat Commun 2021;12:267. .